Please login to the form below

Not currently logged in
Email:
Password:

Marschall Runge joins Lilly’s board of directors

Will serve on the pharma company's Science and Technology, and Public Policy and Compliance Committees

Lilly Marschall Runge Lilly has added academic experience to its board of directors with the appointment of Dr Marschall Runge, who is executive dean for the School of Medicine at the University of North Carolina (UNC).

Dr Runge will serve on Lilly's Science and Technology Committee and the Public Policy and Compliance Committee, where he will use his years of experience in medicines research and healthcare to provide advice on company strategies.

This experience includes his current role at UNC, where he provides overall academic and clinical leadership for the School of Medicine.

Dr Runge also currently serves as principal investigator and director of the North Carolina Translational and Clinical Sciences (NC TraCS), one of 60 medical research institutions that form a national consortium to improve the way biomedical research is conducted across the US.

His previous positions include faculty member at Harvard's Massachusetts General Hospital and associate professor of medicine at Emory University.

“Dr Runge brings to the Lilly board a broad background in healthcare, with extensive experience as a practicing physician, clinical researcher, and dean of a major academic medical institution,” said Dr John Lechleiter, Lilly's chairman, president and CEO.

“His appreciation of the importance of scientific research, coupled with his first-hand experience in patient care, will help Lilly deliver on its commitment to discover and develop innovative medicines that make a difference for patients in need."

30th August 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics